Table 1.
Studies using total cfDNA to predict patient prognosis.
| Cancer Type | # of Patients | cfDNA concentration |
PFS HR | OS HR | Additional Info | Citation |
|---|---|---|---|---|---|---|
| PDAC | 74 | >9.71 ng/mL | 6.85 | 4.16 | Average of cfDNA concentration before and after chemotherapy treatment. | [59] |
| PDAC | - | - | 1.96 | 3.39 | Subgroup analysis of cfDNA during treatment. |
[60] |
| PCa | - | >cut-off | log(HR) = 0.84 | log(HR) = 0.60 | Meta-analysis of studies using different cut-off points. | [61] |
| CRPC | - | >cut-off | log(HR) = 0.65 | log(HR) = 0.59 | Meta-analysis of studies using different cut-off points. | [61] |
| MBC | 194 | >0.306 ng/uL | 1.193 | 1.199 | Majority of samples were collected during treatment. |
[62] |
| MBC | 117 | high cfDNA | 1.64 | 2.73 | High cfDNA was determined by comparing to previous samples. HR based on comparing low and high cfDNA levels. |
[63] |
| mCRC | 1076 | >cut-off | - | 2.39 | Meta-analysis of studies using different cut-off points. | [64] |
| mCRC | 43 | >26 ng/mL | 1.51 | 2.02 | PFS and OS determined from samples before treatment. | [65] |
| NSCLC | - | >cut-off | 1.32 | 1.64 | meta-analysis of studies using different cut-off points. | [66] |
| NSCLC | 177 | >70 ng/mL | 2.6 | 2.63 | PFS and OS determined from samples before treatment. | [67] |
Abbreviations: PDAC: pancreatic ductal adenocarcinoma; PCa: prostate cancer; CRPC: castration resistant prostate cancer; MBC: metastatic breast cancer; mCRC: metastatic colorectal cancer; NSCLC: non-small cell lung cancer.